AB
AUPH icon

Amalgamated Bank’s Aurinia Pharmaceuticals AUPH Stock Holding History

Amalgamated Bank’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,750
Closed -$60K – 1728
2025
Q4 		$60K Sell
3,750
-23
-0.6% -$326 ﹤0.01% 1788
2025
Q3 		$42K Sell
3,773
-899
-19% -$9.82K ﹤0.01% 1891
2025
Q2 		$40K Hold
4,672
– – ﹤0.01% 1884
2025
Q1 		$38K Buy
4,672
+16
+0.3% +$130 ﹤0.01% 1855
2024
Q4 		$42K Hold
4,656
– – ﹤0.01% 1872
2024
Q3 		$34K Hold
4,656
– – ﹤0.01% 1959
2024
Q2 		$27K Hold
4,656
– – ﹤0.01% 2013
2024
Q1 		$23K Sell
4,656
-14,606
-76% -$99.1K ﹤0.01% 2069
2023
Q4 		$173K Sell
19,262
-1,385
-7% -$11.4K ﹤0.01% 1839
2023
Q3 		$160K Hold
20,647
– – ﹤0.01% 1854
2023
Q2 		$200K Buy
20,647
+1,932
+10% +$20.1K ﹤0.01% 1821
2023
Q1 		$205K Sell
18,715
-2,816
-13% -$24.8K ﹤0.01% 1794
2022
Q4 		$93K Hold
21,531
– – ﹤0.01% 2161
2022
Q3 		$162K Buy
21,531
+343
+2% +$2.97K ﹤0.01% 1927
2022
Q2 		$213K Buy
+21,188
New +$237K ﹤0.01% 1852

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Amalgamated Bank's AUPH Position: Q1 2026 in Review

Amalgamated Bank sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2026, closing a stake of 3,750 shares — an estimated $60K sold.

Amalgamated Bank first reported a position in AUPH in Q2 2022 and held it in 15 quarters. The position peaked at $213K in Q2 2022. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Amalgamated Bank reported no remaining Aurinia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 3,750 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $60K.
  • Amalgamated Bank first reported a position in Aurinia Pharmaceuticals in Q2 2022 and held it in 15 quarters.
  • Amalgamated Bank's Aurinia Pharmaceuticals position peaked at $213K in Q2 2022.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.